A Study to Evaluate the Effects of a Dietary Supplement on Weight Management and Appetite Control

Inclusion Criteria: * Male or female. * Aged 18 to 65 years. * Anyone currently experiencing issues regarding all of the following: healthy weight management * appetite management and/or food cravings * energy levels. * Resides in the United States. * Body Mass Index (BMI) ≥ 27.0 and \< 35.0 kg/m². * Anyone who is generally healthy - does not live with any uncontrolled chronic disease. * Willing to follow the study protocol. * Willing to maintain current diet, physical activity, and lifestyle habits for the study duration. * Willing to abstain from alcohol consumption during the study period. Exclusion Criteria: * Current use or use within three months of GLP-1 receptor agonists (e.g., semaglutide/Ozempic/Wegovy, liraglutide/Saxenda/Victoza, tirzepatide/Mounjaro/Zepbound, or dulaglutide/Trulicity) or any prescription weight-loss medication. * Concurrent use of overlapping weight-management dietary supplements that participants are unwilling to discontinue for the study duration. * Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders. * Anyone who is currently undergoing treatment for cancer, or has had a serious illness requiring hospitalization in the last 3 months. * Currently undergoing or planning to undergo any significant medical procedures in the next six weeks. * Currently enrolled in a medically supervised weight-loss program, or has a history of bariatric surgery within the past 12 months. * Any women who are pregnant, breastfeeding, or trying to conceive (or who will be at any point during the study period). * Heavy drinkers or drug users. * A heavy drinker is considered to be a woman who drinks 8 or more alcoholic drinks per week or a man who drinks 15 or more alcoholic drinks per week. * Active or historical eating disorder (e.g., anorexia nervosa, bulimia nervosa, binge eating disorder). * Known allergy or hypersensitivity to any ingredient in the study product or placebo. * Diagnosed diabetes (type 1 or type 2) or use of insulin or antidiabetic medications (e.g., metformin). * Known cardiovascular disease or uncontrolled hypertension. * Clinically significant liver disease or known abnormal liver function. * Currently testing, or planning to in the next six weeks, a product for another research study.